Experts highlight the need to move beyond conventional cost-effectiveness analysis

ISPOR, the professional society for health economics and outcomes research, held a panel session this afternoon, "Should We Move Beyond Conventional Cost-Effectiveness Analysis? If So, How? [IP5]," at ISPOR 2018 in Baltimore, MD, USA.

Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA moderated the panel. Panelists included: Peter J. Neumann, ScD, Tufts Medical Center, Boston, MA, USA; Charles E. Phelps, PhD, MBA, University of Rochester, Rochester, NY, USA; and Jeroen P. Jansen, PhD, Precision Health Economics, Los Angeles, CA, USA.

The traditional structure of cost-effectiveness analysis (CEA) compares health interventions in terms of incremental costs to incremental gains or losses in quality-adjusted life years. CEA is often considered the "gold standard" for the assessment of value for healthcare decision making, but even its proponents acknowledge its limitations.

As healthcare systems move toward value-oriented decision making, greater flexibility in decision-analytic approaches is needed. Some have called for including broader components of value in analyses, such as health equity. Others have argued that the QALY does not sufficiently capture treatment attributes that are important to certain decision makers, especially patients. The panel discussed alternative approaches to achieve the goal of greater flexibility.

Dr Lakdawalla moderated and provided an overview of the recent debates about recommended methods for assessing relative value and making resource decisions in healthcare. Dr Neumann reviewed the evolving field of CEA and its current challenges. Dr Phelps shared his expertise in multi-criteria decision analysis (MCDA), which has been proposed as a way of evolving healthcare decision analysis and addressing some limitations of CEAs. Dr Jansen shared information on the recent efforts to incorporate both CEA and MCDA into value-focused, open-source decision tools designed to improve the ability of CEA to respond rapidly to the emergence of new evidence.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Using AI to foster productivity in pharmaceutical research and development